{"id":74649,"date":"2024-03-23T21:38:05","date_gmt":"2024-03-23T21:38:05","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-ventyx-biosciences-inc-of-class-action-lawsuit-and-upcoming-deadlines-vtyx\/"},"modified":"2024-03-23T21:38:05","modified_gmt":"2024-03-23T21:38:05","slug":"shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-ventyx-biosciences-inc-of-class-action-lawsuit-and-upcoming-deadlines-vtyx","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-ventyx-biosciences-inc-of-class-action-lawsuit-and-upcoming-deadlines-vtyx\/","title":{"rendered":"SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines \u2013 VTYX"},"content":{"rendered":"
\n

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (\u201cVentyx\u201d or the \u201cCompany\u201d) (NASDAQ: VTYX) and certain officers.\u00a0\u00a0 The class action, filed in the United States District Court for the Southern District of California, and docketed under 24 -cv-00415, is on behalf of all persons and entities other than Defendants who purchased or otherwise acquired: (a) Ventyx common stock pursuant and\/or traceable to the Offering Documents (defined below) issued in connection with the Company\u2019s initial public offering conducted on or about October 21, 2021 (the \u201cIPO\u201d or \u201cOffering\u201d); and\/or (b) Ventyx securities between October 21, 2021 and November 6, 2023, both dates inclusive (the \u201cClass Period\u201d).\u00a0 Plaintiff pursues claims against the Defendants under the Securities Act of 1933 (the \u201cSecurities Act\u201d) and the Securities Exchange Act of 1934 (the \u201cExchange Act\u201d).<\/p>\n

If you are a shareholder who purchased or otherwise acquired (a) Ventyx common stock pursuant and\/or traceable to the Offering Documents issued in connection with the Company\u2019s initial public offering; and\/or (b) Ventyx securities during the Class Period, you have until April 30, 2024, to ask the Court to appoint you as Lead Plaintiff for the class.\u00a0 A copy of the Complaint can be obtained at www.pomerantzlaw.com<\/u><\/a>.\u00a0 To discuss this action, contact Danielle Peyton at newaction@pomlaw.com<\/u><\/a> or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.\u00a0<\/p>\n

[Click here for information about joining the class action]<\/u><\/strong><\/a><\/p>\n

Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.\u00a0 The Company\u2019s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn\u2019s disease.\u00a0 In 2022, Ventyx initiated a Phase 2 clinical trial of VTX958 for the treatment of moderate to severe plaque psoriasis (the \u201cPhase 2 SERENITY Trial\u201d).<\/p>\n

On September 29, 2021, Ventyx filed a registration statement on Form S-1 with the Securities and Exchange Commission (\u201cSEC\u201d) in connection with the IPO, which, after several amendments, was declared effective by the SEC on October 20, 2021 (the \u201cRegistration Statement\u201d).<\/p>\n

On October 21, 2021, Ventyx filed a prospectus on Form 424B4 with the SEC in connection with the IPO, which incorporated and formed part of the Registration Statement (the \u201cProspectus\u201d and, collectively with the Registration Statement, the \u201cOffering Documents\u201d).<\/p>\n

The complaint alleges that the Offering Documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation.\u00a0 In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company\u2019s business, operations, and prospects.\u00a0 Specifically, the Offering Documents and Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) VTX958 was less effective in treating psoriasis than Defendants had led investors to believe; (ii) as a result, VTX958\u2019s clinical and\/or commercial prospects were overstated; (iii) accordingly, the Company had misrepresented its ability to develop and commercialize effective product candidates; (iv) Ventyx\u2019s post-IPO business prospects were thus inflated; and (v) as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n

On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.\u00a0 Therein, the Company disclosed that \u201c[a]lthough the trial achieved its primary endpoint, the magnitude of efficacy observed did not meet our internal target to support the advancement of VTX958 in plaque psoriasis.\u201d\u00a0 Based on these results, the Company announced that it \u201cwill terminate ongoing activities in the Phase 2 plaque psoriasis trial effective immediately\u201d and \u201cterminate the ongoing Phase 2 trial of VTX958 in psoriatic arthritis.\u201d<\/p>\n

On this news, Ventyx\u2019s common stock price fell $11.36 per share, or 80.62%<\/em><\/strong>, to close at $2.73 per share on November 7, 2023.<\/p>\n

Then, on November 22, 2023, Ventyx disclosed in a filing with the SEC on Form 8-K that the Company\u2019s President and Chief Medical Officer Defendant William J. Sandborn would cease to serve in those roles.<\/p>\n

As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.<\/p>\n

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com<\/u><\/a>.<\/p>\n

Attorney advertising. \u00a0Prior results do not guarantee similar outcomes.<\/p>\n

CONTACT:<\/strong><\/p>\n

Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com<\/u><\/a>
<\/a>888-476-6529 ext. 7980<\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) — Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (\u201cVentyx\u201d or the \u201cCompany\u201d) (NASDAQ: VTYX) and certain officers.\u00a0\u00a0 The class action, filed in the United States District Court for the Southern District of California, and docketed under 24 -cv-00415, is on […]<\/p>\n","protected":false},"author":2,"featured_media":74650,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/media\/ZGMxMTY3M2UtMzVlZi00MmVmLTk3YjAtZDRkZjhjNjBiN2NjLTEwMjkyMTc=\/tiny\/Pomerantz-LLP.png","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-74649","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/74649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=74649"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/74649\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/74650"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=74649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=74649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=74649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}